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Open acAbstract Aim: Lymph node metastases inﬂuence prognosis and outcome in patients with
bladder and prostate cancer. Cross sectional imaging criteria are limited in detecting metasta-
ses in normal sized lymph nodes. This prospective study assessed the diagnostic accuracy of
ultrasmall superparamagnetic particles of iron oxide (USPIO)-enhanced magnetic resonance
imaging (MRI) for the detection of metastases in normal sized lymph nodes using extended
pelvic lymph node dissection (ePLND) and histopathology as the reference standard.
Methods: Seventy-ﬁve patients (bladder cancer, n = 19, prostate cancer n = 48, both, n = 8)
were examined using 3T MR before and after USPIO-administration. A preoperative reading
with two readers in consensus and a second postoperative reading with three independent
blinded readers were performed. Results were correlated with histopathology and diagnostic
accuracies were calculated for all readings.
Results: A total of 2993 lymph nodes were examined histopathologically. Fifty-four meta-
static nodes were found in 20/75 patients (26.7%). The ﬁrst reading had a sensitivity of
55.0%, speciﬁcity of 85.5%, positive predictive value (PPV) of 57.9%, negative predictive value
(NPV) of 83.9%, and diagnostic accuracy (DA) of 77.3% on a per patient level. The second34
y was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines and
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rtment of Radiology, Neuroradiology and Nuclear Medicine, Institute for Diagnostic, Interventional, and
ty Hospital Bern, Freiburgstrasse 10, Bern 3010, Switzerland. Tel.: +41 31 632 2939; fax: +41 31 632 4874.
l.ch (H.C. Thoeny).
cess under CC BY-NC-ND license. 
M. Triantafyllou et al. / European Journal of Cancer 49 (2013) 616–624 617reading had a mean sensitivity of 58.3%, speciﬁcity of 83.0%, PPV of 58.0%, NPV of 84.4%
and DA of 76.4% on a per patient level. The majority of missed metastases were smaller than
5 mm in short axis diameter.
Conclusions: USPIO-enhanced MRI in bladder and prostate cancer patients allows detection
of metastases in normal sized lymph nodes and might guide the surgeon to remove suspicious
lymph nodes not included in standard PLND.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license. 1. Introduction
Metastatic involvement of lymph nodes in patients
with bladder and/or prostate cancer has a strong impact
on treatment decisions and patient prognosis.1–5
Although size and morphology are used to evaluate
lymph node involvement using conventional cross sec-
tional imaging, there is a limited ability to detect metas-
tases in normal sized lymph nodes using these criteria.
Therefore, an extended template pelvic lymph node dis-
section (ePLND) is preferred by many urologists, even
when no lymph node metastases are detectable on com-
puterised tomography (CT) or magnetic resonance
imaging (MRI) (N0 staging).6–8 In fact, occult lymph
node metastases are found in template lymphadenec-
tomy in up to 25% of patients staged as N0.5,7,9,10 It is
also known that lymph node metastases in patients with
bladder and/or prostate cancer do not necessarily follow
a predeﬁned pathway of spread,11 and that even when
PLND is extended to the mid-upper third of the com-
mon iliac vessels, only about 90% of the primary lym-
phatic landing sites are removed.6–8,12 Thus, ePLND
remains the gold standard for the detection of lymph node
metastases in patients with urogenital cancers.13–16
Although restricted lymph node dissection and targeted
local treatments are desirable, these can only be
performed if accurate preoperative lymph node staging
is possible.
In order to improve detection of lymph node metas-
tases, the use of lymphotropic ultrasmall superparamag-
netic particles of iron oxide (USPIO) has been
investigated in several urogenital malignancies.17–26
Promising results with apparent diagnostic accuracies
up to 97.3% have been published; however, none of
the previous studies were based on ePLND. Therefore,
the accuracy of the published negative predictive values
is limited. Moreover, the majority of the published stud-
ies included patients with enlarged lymph nodes, and
few authors commented on the detection of metastases
in normal sized lymph nodes after the administration
of USPIO.18,26
Thus, the aim of our study was to prospectively assess
the diagnostic accuracy of USPIO-enhanced MRI for
the detection of lymph node metastases in bladder
and/or prostate cancer patients with N0 staging based
on conventional MR/CT imaging using meticulous
ePLND and histopathology as the reference standard.2. Methods
2.1. Patients
Between May 2008 and March 2010, 256 patients
with histologically proven invasive bladder and/or pros-
tate cancer were scheduled for radical cysto-/prostatec-
tomy and ePLND (Fig. 1). Patients with prior
chemotherapy or radiotherapy in the pelvic area,
enlarged pelvic lymph nodes on previous CT/MRI
(threshold of 10 mm in short axis diameter for bladder
and 8 mm for prostate cancer), positive bone scintigra-
phy, hemochromatosis, gadolinium administration 48 h
prior to the examination, known iron or dextrane
allergy or MR contraindications were excluded. Finally,
84 of these patients were initially eligible for study
inclusion.
Nine of these 84 patients were secondarily excluded
due to the detection of bone metastases on study MRI
contraindicating surgery (n = 1), detection of enlarged
lymph nodes on the MR images (n = 2), unacceptable
image quality (n = 1), inductive chemotherapy following
positive imaging results (n = 2), allergic reaction to
USPIO (n = 1), refusal of surgery (n = 1) or cancellation
of surgery due to poor performance status (n = 1). A
total of 75 patients qualiﬁed for ﬁnal image analysis
and represented the study cohort (Table 1).
2.2. Imaging
All patients were examined on a 3T MR unit (Trio,
Siemens Medical, Erlangen, Germany). Two identical
pelvic MRI exams were performed before and 24–36 h
after intravenous administration of 2.6 mg iron/kg body
weight of USPIO (Ferumoxtran-10, Sinerem; Guerbet,
Roissy, France). One milligram of Glucagon (GlucaGen,
Novo Nordisk, Switzerland) was administrated intrave-
nously at the beginning of each MR exam. Adverse
events such as urticaria (n = 2), hot ﬂash, hypertension
and headache (n = 2), swelling of neck and nose
(n = 1) and diarrhoea (n = 2) occurred in seven (11%)
patients. In an eighth patient USPIO injection was
stopped when dyspnoea and hypertension occurred after
injection of 2 ml USPIO solution. Symptoms were self-
limiting in all cases.
A 3D T1-weighted (T1w) sequence with 0.8 mm3
reconstructed isotropic voxels, and an iron-sensitive
Bladder and/or prostate cancer
patients planned for surgery
(N=256) Exclusions:
Prior radio-/chemotherapy (N=29)
Organisational reasons (N=70)
Change of treatment or enlarged LN (N=49)
Patients included into the study Contraindications to MRI (N=24)
without enlarged lymph nodes
(N 84)=
Exclusion: 
Allergy (N=1)
1. First MRI + USPIO
2 Second MRI 24-36 hrs later. 
(N=84) 
Exclusions:
Bone metastases (N=1)
Chemotherapy (N=2)
N (N 2)Final inclusion o surgery =
Enlarged LN (N=2)(N=75) 
Poor image quality (N=1)
First reading
Surgery
1 Excision of suspicious LN. 
2. ePLND
Histology
Second readings
Fig. 1. Trial progress ﬂowchart. MRI, magnetic resonance imaging; ePLND, extended pelvic lymph node dissection; USPIO, ultrasmall
superparamagnetic particles of iron oxide; LN, lymph nodes.
Table 1
Patient and tumour characteristics including demographics and
postoperative tumour and lymph node staging.
Patient characteristics Median Range
Age (years) 64 43–82
Days between MR and surgery 8 0–33
Gleason score 7 5–9
Number of LN sampled per patient 39 17–68
Patient characteristics Participants
Gender
Male 66
Female 9
Tumour type
Bladder cancer 19
Prostate cancer 48
Bladder and prostate cancer 8
Bladder cancer staging
pT1G3 2
pT2G any 11
pT3G any 12
pT4G any 2
Prostate cancer staging
pT1 2
pT2 31
pT3 18
pT4 5
Abbreviations: MR= magnetic resonance; LN = lymph nodes.
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voxels were performed in the coronal plane through the
entire pelvis. In addition, a 3D T1w-VIBE sequence was
obtained during the second MRI exam to facilitate the
exact anatomical localisation of the lymph nodes in rela-
tion to the blood vessels. Additional diﬀusion-weighted
MRI sequences were performed but not evaluated in
the present study.2.3. Radiological evaluation
Radiological evaluation was performed on a picture
archiving and communication system (PACS) worksta-
tion (PACS R11.4.1, 2009; Philips, Best, Netherlands;
Sectra, Linko¨ping, Sweden). A preoperative reading
was performed by two readers in consensus out of a pool
of four (M.T., H.C.T., G.P., J.M.F. with 3, 12, 5 and
8 years of experience in body MRI, respectively). After
ﬁnishing the patient accrual a second postoperative
reading was performed by three readers independently
(G.P., A.C. and M.T.), blinded to histopathology results
and clinical information. Reader A (G.P.) was a radiol-
ogist with six years of MRI experience and one year of
experience in USPIO-enhanced MRI, Reader B (A.C.)
had ﬁve years of experience in MRI and a short training
M. Triantafyllou et al. / European Journal of Cancer 49 (2013) 616–624 619in reading USPIO-enhanced MRI. Reader C (M.T.) was
a radiologist with ﬁve years of MRI experience and two
years of USPIO-enhanced MRI experience.
2.4. Image interpretation
A node-by-node analysis was performed on axially
reconstructed (2 mm slices) T2w-sequences by compar-
ing images before and after USPIO-administration.
Lymph nodes were considered benign when a signal
intensity loss of >15% on the post-USPIO images was
observed,27 and malignant when signal intensity was lar-
gely maintained in areas which did not correspond to
hilar fat (Fig. 2). Localisation of suspicious nodes was
indicated on an anatomical landmark chart dividing
the pelvis into ten regions (Fig. 3). Imaging results were
reviewed with the responsible surgeon after the ﬁrst
reading to ensure removal of suspicious lymph nodes.
The entire time of evaluation was noted for all
readings.Fig. 2. Typical example of ultrasmall superparamagnetic particles of iron o
reconstructed images before (A) and after (B) the administration of USPIO
arrow) shows a decrease in signal intensity after the uptake of USPIO; the
medial signal decrease after the administration of USPIO.
Fig. 3. Anatomic landmark chart divided into 10 regions according to the
right (1b) and left (4b), distal external iliac right (1a) and left (4a), proxima
left (5a).2.5. Surgery
Prior to PLND, lymph nodes indicated on the land-
mark chart were resected, labelled and sent for separate
histopathological examination. An ePLND including
the area of the crossing of the ureters and the common
iliac vessels was then performed.6,12 Specimens from
ePLND were labelled according to the ten anatomical
regions.2.6. Histopathological evaluation
Resected lymph nodes were ﬁxed overnight in 4% for-
malin, degreased with acetone, cut into 2–4 mm thick
tissue slices and completely embedded in paraﬃn. One
section per paraﬃn block was taken for histopatholo-
gical examination. Two experienced pathologists evalu-
ated histopathological ﬁndings that could inﬂuence the
uptake of USPIO in each lymph node, including follicu-
lar hyperplasia, sinus histiocytosis, marked ﬁbrosis,xide (USPIO) uptake in positive and negative lymph nodes. Axial T2w-
in a 67-year-old prostate cancer patient. The benign lymph node (black
malignant lymph node (white arrow) shows only partial posterior and
iliac vessels: common iliac right (3) and left (6), proximal external iliac
l internal iliac right (2b) and left (5b), distal internal iliac right (2a) and
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Fig. 4. Receiver operating characteristic (ROC) curves showing the
diagnostic performance of the ﬁrst (prospective) and second (A, B, C)
readings on a per patient level.
Table 2
Patients with unilateral and bilateral pelvic lymph node metastases.
Number of lymph node
metastases per patient
Patients with
unilateral pelvic
involvement
Patients with
bilateral pelvic
involvement
1 8 0
2 2 3
3 3 1
4 0 2
>4 0 1
620 M. Triantafyllou et al. / European Journal of Cancer 49 (2013) 616–624marked fatty involution and neoplastic tissue. Sizes of
positive lymph nodes and metastases were measured in
two planes and localisations on the anatomic landmark
chart were recorded.
2.7. Statistics
All included patients were staged N0. Statistical per-
formance measures (i.e. sensitivity, speciﬁcity, positive
predictive value (PPV), negative predictive value (NPV)
and accuracy) of the USPIO readings as compared to
histopathological ﬁndings were calculated both on a
per patient and per pelvic side level for both readings.Fig. 5. Example of a correctly diagnosed positive lymph node metastasis loc
arrow) shown in axial reconstructed T2w-images after ultrasmall superpara
acquired T2w-images (B) and parasagittal reconstructions (C) in a 60-year-
show USPIO uptake. Such a metastasis may have easily been missed in exte
results.Statistical analyses were performed using Microsoft
Excel with the Analyse-it plugin (Release 2.22/2010;
Analyse-it Software Ltd., Leeds, United Kingdom;
Microsoft, Redmont, USA). Receiver operating charac-
teristic (ROC) curve analyses were performed using his-
topathological results as gold standard (Fig. 4).
Interobserver agreement between the three blinded
readers in the second readingwas assessed on aper patient
level using Fleiss’s kappa statistic and Randolph’s free-
marginal multirater kappa statistic for all four readings,
where a kappa of 1.0 indicates perfect agreement.28,293. Results
3.1. Histopathological evaluation
A total of 2993 lymph nodes were identiﬁed in 75
patients. Fifty-four metastases (1.8% of resected lymph
nodes) were found in 20/75 (26.7%) patients. Thirteen
patients presented with unilateral metastases (Table 2).
Histopathology reported four metastatic lymph nodes
having a short axis diameter >10 mm. Most of the
malignant lymph nodes had a short axis diameter
65 mm (41/54) (Fig. 5). The majority of the metastases
themselves had a short axis diameter 65 mm (50/54),
and 43/54 were 63 mm in short axis diameter (Table 3).alised between the left proximal internal and external iliac artery (black
magnetic particles of iron oxide (USPIO) administration (A), coronally
old patient with bladder and prostate cancer. This lymph node did not
nded pelvic lymph node dissection (ePLND) in the absence of imaging
Table 3
Number of lymph node metastases classed by size of lymph nodes and
metastases as determined by histopathology. Note that the largest
lymph nodes and metastases (*) were not visible on magnetic resonance
imaging (MRI) retrospectively, which may be related to the diﬀering
planes of MR imaging and histopathological sections.
Size (mm) Lymph nodes (n) Metastases (n)
Short axis Short axis Long axis
61 4 20 16
1.1–3.0 12 23 11
3.1–5.0 25 7 18
5.1–8.0 6 3 3
8.1–10.0 3 0 1
>10 4* 1* 5*
Table 4
Diagnostic performance per patient (n = 75).
Per patient:
statistical
performance
measures
First
reading
Second reading
Reader
A
Reader
B
Reader
C
Average
True positive 11 11 11 13 11.7
False positive 8 7 16 5 9.3
False negative 9 9 9 7 8.3
True negative 47 48 39 50 45.7
Sensitivity (%) 55.0 55.0 55.0 65.0 58.3
Speciﬁcity (%) 85.5 87.3 70.9 90.9 83.0
Positive
predictive
value (%)
57.9 61.1 40.7 72.2 58.0
Negative
predictive
value (%)
83.9 84.2 81.3 87.7 84.4
Diagnostic
accuracy (%)
77.3 78.7 66.7 84.0 76.4
Table 5
Diagnostic performance per pelvic side (n = 150).
Per pelvic side:
statistical
performance
measures
First
reading
Second reading
Reader
A
Reader
B
Reader
C
Average
True positive 12 11 11 17 13
False positive 13 12 24 7 14.3
False negative 14 15 15 9 13
True negative 111 112 100 117 109.7
Sensitivity (%) 46.2 42.3 42.3 65.4 50.0
Speciﬁcity (%) 89.5 90.3 80.6 94.4 88.4
Positive
predictive
value (%)
48.0 47.8 31.4 70.8 50.0
Negative
predictive
value (%)
88.8 88.2 87.0 92.9 89.4
Diagnostic
accuracy (%)
82.0 82.0 74.0 89.3 81.8
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(Table 3).3.2. Diagnostic performance on a per patient level
In the ﬁrst reading a sensitivity of 55.0%, speciﬁcity
of 85.5%, PPV of 57.9%, NPV of 83.9% and diagnostic
accuracy (DA) of 77.3% were observed (Table 4), and
11/20 patients were correctly diagnosed as positive. In
the second reading, combining the results of all three
independent readers gave a mean sensitivity of 58.3%,
mean speciﬁcity of 83.0%, mean PPV of 58.0%, mean
NPV of 84.4% and mean DA of 76.4% (Table 4). Read-
ers A, B and C correctly detected metastases in 11/20,
11/20 and 13/20 patients, respectively, and gave false
negative readings in 9/20, 9/20 and 7/20 patients
(Table 4).3.3. Diagnostic performance on a per pelvic side level
On a per pelvic side level (n = 150) a sensitivity of
46.2%, speciﬁcity of 89.5%, PPV of 48.0%, NPV of
88.8% and DA of 82.0% were reported in the ﬁrst read-
ing. Metastases were correctly detected in 12/26 positive
sides. In the second reading a mean sensitivity of 50.0%,
speciﬁcity of 88.4%, PPV of 50.0%, NPV of 89.4% and
DA of 81.8% were observed for readers A, B and C,
respectively (Table 5).3.4. Detection of small metastases
Apart from one metastasis with a short axis diameter
of >5 mm which was missed by one reader, all other
missed metastases were 65 mm, and most were
63 mm in short axis diameter. A total of 17 metastases
with a short axis diameter 65 mm were correctly
detected by the most experienced reader. Some anatom-
ical regions were particularly diﬃcult to evaluate for
small (65 mm) metastases, including the perivesical
and periprostatic area and lymph nodes along the com-
mon iliac vessels. A periprostatic metastasis of
0.5  0.2 mm and a metastasis in the perivesical fat of
0.28  0.28 mm were missed in all four readings. Small
metastases close to the common iliac vessels also
remained undetected in all four readings (Table 5 and
Fig. 6).
False positive results could be attributed in single
cases to marked ﬁbrosis or lipomatosis (Fig. 7).3.5. Interobserver agreement of second reading
Interrater agreement for the four readings yielded a
Fleiss’ kappa of 0.77 and a Randolph’s multirater kappa
of 0.54, indicating a moderate interrater agreement.28,293.6. Time of evaluation for the MRI readings
The time of evaluation for the preoperative MRI
reading ranged from 10 to 93 min with a median value
Fig. 6. Example of a false negative lymph node (black arrow). Axial reconstructed T2w-images before (A) and after (B) the administration of
ultrasmall superparamagnetic particles of iron oxide (USPIO) in a 68-year-old patient with prostate cancer. The lymph node shows a signal
intensity decrease of 55%. Histopathology showed a metastasis of 2.3  0.8 mm (short arrows, C) in a lymph node by the left common iliac artery.
No other metastatic lymph nodes were identiﬁed in this patient.
Fig. 7. Example of a false positive lymph node (white arrow). T2w-parasagittal reconstructed images are shown before (A) and after (B) the
administration of ultrasmall superparamagnetic particles of iron oxide (USPIO) in a 66-year-old patient with bladder and prostate cancer. The
lymph node did not show any signiﬁcant drop of signal intensity after the administration of USPIO. Parasagittal reconstructed VIBE images show
the localisation of the suspicious lymph node in relation to the vessels (C). Histopathology shows the presence of extensive fatty tissue replacing
parts of the lymph node (lipomatosis) (D).
622 M. Triantafyllou et al. / European Journal of Cancer 49 (2013) 616–624of 45 min per patient and for the second reading from 10
to 47 min with a median of 32 min per patient.
4. Discussion
Our results indicate that USPIO-enhanced MRI
enables detection of lymph node metastases in normal
sized lymph nodes in bladder and prostate cancer
patients staged as metastasis free (N0) based on conven-
tional cross sectional imaging methods. These results are
in agreement with previously published data which show
that USPIO-enhanced MRI improves pelvic lymph node
staging in patients with urogenital malignancies.18–20,26
Despite the limited spatial resolution of MRI, we were
even able to detect lymph node metastases smaller than
5 mm. Using ePLND as reference standard, the results
of the present study provide an accurate portrayal of
the diagnostic potential of USPIO-enhanced MRI.
Due to the still substantial number of false negative
readings, USPIO-enhanced MRI cannot replace
ePLND. However, we have demonstrated that USPIO-enhanced MRI provides valuable additional informa-
tion which could guide the surgeon to extend the region
of standard PLND.
The diagnostic accuracies reported here are relatively
low compared to previous literature. This may be par-
tially attributed to the exclusion of patients with enlarged
lymph nodes from this study. In a study including blad-
der cancer patients, those authors found 38/50 positive
lymph nodes larger than 10 mm.26 In another study
including prostate cancer patients, 38/63 positive nodes
fulﬁlled the morphological imaging criteria of malig-
nancy.18 The inclusion of lymph nodes with suspicious
morphology partially explains the higher sensitivity and
positive predictive values reported in these studies.
Although our ﬁnal histopathological results showed four
metastatic nodes having a short axis diameter >10 mm,
these nodes were not detectable on retrospective review
of the MR images. This may be related to the diﬀering
planes of MR imaging and histopathological sectioning.
Another strength of the present study is the high
number of lymph nodes that were resected (mean of
M. Triantafyllou et al. / European Journal of Cancer 49 (2013) 616–624 62339 per patient) explaining the lower diagnostic accuracy
compared to previous studies.6,12 Additionally, a metic-
ulous histopathological analysis of each lymph node
lead to the detection of micrometastases as small as
0.1  0.2 mm. This is signiﬁcant because the likelihood
that micrometastases will be found increases with the
number of normal sized nodes removed7 and the sensi-
tivity of our diagnostic assays was correspondingly
lower. In a study of prostate cancer patients, 334 lymph
nodes were resected or biopsied in 80 patients which cor-
responds to an average of four nodes per patient, sug-
gesting that primarily enlarged nodes and nodes
suspicious for metastases on USPIO-enhanced MRI
were analysed.18 This results in an overestimation of
the diagnostic accuracy since the number of missed
metastases in normal sized LNs is unknown in the
absence of histopathological results.
As in previously published literature,18,19 false posi-
tive results were often found in conjunction with condi-
tions inﬂuencing the normal architecture and function of
lymph nodes such as ﬁbrosis, sinus histiocytosis, lipoma-
tosis or focal fatty involution which may lead to hetero-
geneous uptake of USPIO. However, from a clinical
point of view, false positive ﬁndings are of lesser impor-
tance than false negatives since the removal of false posi-
tive nodes does not harm the patient, while missing
metastatic nodes can negatively impact patient progno-
sis. Thus, the relatively high negative predictive value
on a per patient level in our study demonstrates the
potentially useful role of USPIO-enhanced MRI in
patient management.
In contrast to previous studies, our investigation was
performed on a 3T MR unit providing improved image
quality relative to 1.5T MR. This allowed for high image
resolution with reconstructed isotropic voxel sizes as
small as 0.8 mm3, which was crucial to the detection of
small metastases. However, the majority of metastases
with a short axis diameter 63 mm were still missed.
Our study has several limitations. Firstly, node-by-node
correlations of MRI with histopathology could not be
performed. However, the localisation of lymph nodes
in ten well deﬁned anatomical regions allowed nodes
seen on MRI to be targeted surgically. Secondly, we
refrained from individual analysis of the ten sectors as
initially planned, because the boundaries of surgical
resection were ill deﬁned and varied depending on the
individual surgeon. Therefore, we performed our
analysis per pelvic side and per patient. Thirdly,
although ePLND was performed with a high number
of lymph nodes resected per patient, it is possible that
single lymph nodes were missed.
Finally, it must be mentioned that USPIO is not cur-
rently approved by health authorities for lymph node
detection, despite several attempts and a large number
of clinical studies. In anticipation of the development
of further USPIO-derivatives, we believe that the pres-ent study is important in providing insight into the diag-
nostic work-up of lymph node metastases and in setting
realistic and clinically relevant imaging goals for future
studies.
The present data show that the use of USPIO-
enhanced MRI in patients with bladder and/or prostate
cancer staged as N0 on conventional cross sectional
imaging enables the accurate detection of metastases
with a short axis diameter of 5 mm and larger. Due to
the number of missed metastases smaller than 3 mm,
lymph node dissection restricted to suspicious nodes
cannot be recommended. However, USPIO-enhanced
MRI has the potential to improve treatment and patient
outcomes by guiding the removal of additional suspi-
cious nodes in pelvic regions not typically included in
standard PLND.
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